Trump has a 'small personal financial interest' in hydroxycholorquine drugmaker. Allies have bigger stakes.
President Trump has been promoting the malaria and lupus drug hydroxychloroquine to treat COVID-19 "with all of the enthusiasm of a real estate developer," even as the medical experts on his coronavirus task force have repeatedly "warned against overselling a drug yet to be proved a safe remedy, particularly for heart patients," The New York Times reports. Some hospitals in Sweden stopped using hodroxycholoriquinine to treat the coronavirus due to adverse side effects, and the International Society of Antimicrobial Chemotherapy rejected a positive French study it had published on the drug, cited by Trump.
Dr. Anthony Fauci, the top U.S. infectious disease officials, has warned publicly and privately against promoting the drug absent studies showing its effectiveness, and "behind the scenes, career health officials have raised even stronger warnings about the risk to some Americans' heart health and other complications, but been warned not to publicly speak out and potentially contradict Trump," Politico reports. "Trump's focus on the drugs ... has increasingly warped his administration's response. Health officials have been told to prioritize the anti-malaria drugs over other projects that scientists believe have more potential to fight the outbreak." So...
"If hydroxychloroquine becomes an accepted treatment, several pharmaceutical companies stand to profit, including shareholders and senior executives with connections to the president," the Times reports. "Trump himself has a small personal financial interest in Sanofi, the French drugmaker that makes Plaquenil, the brand-name version of hydroxychloroquine." Other top Trump donors, allies, golf buddies, and Cabinet officials also have various ties to hydroxychlorquine.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
On the other hand, some hospitals in New York are using the drug to treat COVID-19, with mixed results. Senior administration officials tell Politico that Trump really believes hydroxychloroquine could end the COVID-19 pandemic. Trump has told associates Oracle founder Larry Ellison first pointed him to the drug, and TV personality Dr. Mehmet Oz, Rudy Giuliani, and trade adviser Peter Navarro have boosted his faith. "He thinks that it's the drug that's going to get everyone back to work," one Republican close to the White House told Politico, joking: "Do you have a supply?"
Sign up for Today's Best Articles in your inbox
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Peter has worked as a news and culture writer and editor at The Week since the site's launch in 2008. He covers politics, world affairs, religion and cultural currents. His journalism career began as a copy editor at a financial newswire and has included editorial positions at The New York Times Magazine, Facts on File, and Oregon State University.
-
The Christmas quiz 2024
From the magazine Test your grasp of current affairs and general knowledge with our quiz
By The Week UK Published
-
People of the year 2024
In the Spotlight Remember the people who hit the headlines this year?
By The Week UK Published
-
Crossword: December 25, 2024
The Week's daily crossword
By The Week Staff Published
-
Judges block $25B Kroger-Albertsons merger
Speed Read The proposed merger between the supermarket giants was stalled when judges overseeing two separate cases blocked the deal
By Peter Weber, The Week US Published
-
Rupert Murdoch loses 'Succession' court battle
Speed Read Murdoch wanted to give full control of his empire to son Lachlan, ensuring Fox News' right-wing editorial slant
By Peter Weber, The Week US Published
-
Will Trump (and Sanders) cut credit card rates?
Talking Points Common ground is possible. But there's a catch.
By Joel Mathis, The Week US Published
-
Bitcoin surges above $100k in post-election rally
Speed Read Investors are betting that the incoming Trump administration will embrace crypto
By Peter Weber, The Week US Published
-
What does Trump's Treasury secretary pick mean for the economy?
In the Spotlight Scott Bessent was once a Democratic donor. Now he'll serve Trump.
By Joel Mathis, The Week US Published
-
Enron mystery: 'sick joke' or serious revival?
Speed Read 23 years after its bankruptcy filing, the Texas energy firm has announced its resurrection
By Peter Weber, The Week US Published
-
Is this the end of the free trade era?
Today's Big Question Donald Trump's threat to impose crippling tariffs 'part of a broader turn towards protectionism in the West'
By Elliott Goat, The Week UK Published
-
Big Oil doesn't need to 'drill, baby, drill'
In the Spotlight Trump wants to expand production. Oil companies already have record output.
By Joel Mathis, The Week US Published